Roche posts strong nine-month sales, boosted by new products
Roche (ROG: SIX) today released sales figures for the first nine months of 2018, showing that group sales increased 7%at constant exchange rates and in Swiss francs to 40.08 billion francs $40.48). The company does not reveal any profit figures at the quarterly stage.
Pharmaceuticals Division sales were also up 7% to 37.70 billion francs, driven mainly by Ocrevus (ocrelizumab), Perjeta (pertuzumab), Alecensa (alectinib) and Tecentriq (atezolizumab), as new medicines compensated for the loss of exclusivity on long-time blockbuster drugs.Diagnostics Division sales increased 6% to 9.4 billion francs.
Third-quarter sales rose 7% to 13.97 billion francs, the Swiss pharma giant said, compared with analysts’ average forecast of 13.8 billion francs in a Reuters poll.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze